-
Something wrong with this record ?
Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl- N6-(4-morpholin-4-ylmethyl-phenyl)- 9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations
T. Gucký, E. Řezníčková, T. Radošová Muchová, R. Jorda, Z. Klejová, V. Malínková, K. Berka, V. Bazgier, H. Ajani, M. Lepšík, V. Divoký, V. Kryštof,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV15-28951A
MZ0
CEP Register
- MeSH
- Leukemia, Myeloid, Acute genetics pathology MeSH
- Diamines chemistry metabolism pharmacology MeSH
- Protein Kinase Inhibitors chemistry metabolism pharmacology MeSH
- Protein Conformation MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Drug Discovery * MeSH
- Antineoplastic Agents chemistry metabolism pharmacology MeSH
- Molecular Docking Simulation MeSH
- fms-Like Tyrosine Kinase 3 antagonists & inhibitors chemistry genetics metabolism MeSH
- Structure-Activity Relationship MeSH
- Xenograft Model Antitumor Assays MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. We present novel 2,6,9-trisubstituted purine derivatives with potent FLT3 inhibitory activity. The lead compound 7d displays nanomolar activity in biochemical assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Additionally, a single dose of 7d in mice with subcutaneous MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect observed after administration of the reference FLT3 inhibitor quizartinib.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028475
- 003
- CZ-PrNML
- 005
- 20211207134801.0
- 007
- ta
- 008
- 190813s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.7b01529 $2 doi
- 035 __
- $a (PubMed)29672049
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Gucký, Tomáš, $u Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Faculty of Science , Palacký University , Šlechtitelů 27 , 783 71 Olomouc , Czech Republic. $d 1978- $7 ola2005284374
- 245 10
- $a Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl- N6-(4-morpholin-4-ylmethyl-phenyl)- 9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations / $c T. Gucký, E. Řezníčková, T. Radošová Muchová, R. Jorda, Z. Klejová, V. Malínková, K. Berka, V. Bazgier, H. Ajani, M. Lepšík, V. Divoký, V. Kryštof,
- 520 9_
- $a FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-ITD mutations respond poorly to standard cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. We present novel 2,6,9-trisubstituted purine derivatives with potent FLT3 inhibitory activity. The lead compound 7d displays nanomolar activity in biochemical assays and selectively blocks proliferation of AML cell lines harboring FLT3-ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. The MV4-11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Additionally, a single dose of 7d in mice with subcutaneous MV4-11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect observed after administration of the reference FLT3 inhibitor quizartinib.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemie $x metabolismus $x farmakologie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a diaminy $x chemie $x metabolismus $x farmakologie $7 D003959
- 650 12
- $a objevování léků $7 D055808
- 650 _2
- $a akutní myeloidní leukemie $x genetika $x patologie $7 D015470
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a konformace proteinů $7 D011487
- 650 _2
- $a inhibitory proteinkinas $x chemie $x metabolismus $x farmakologie $7 D047428
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 650 _2
- $a tyrosinkinasa 3 podobná fms $x antagonisté a inhibitory $x chemie $x genetika $x metabolismus $7 D051941
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Řezníčková, Eva $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research , Palacký University and Institute of Experimental Botany AS CR , Šlechtitelů 27 , 783 71 Olomouc , Czech Republic.
- 700 1_
- $a Radošová Muchová, Tereza $u Department of Biology, Faculty of Medicine and Dentistry , Palacký University , Hněvotínská 3 , 775 15 Olomouc , Czech Republic.
- 700 1_
- $a Jorda, Radek $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research , Palacký University and Institute of Experimental Botany AS CR , Šlechtitelů 27 , 783 71 Olomouc , Czech Republic.
- 700 1_
- $a Klejová, Zuzana $u Department of Biology, Faculty of Medicine and Dentistry , Palacký University , Hněvotínská 3 , 775 15 Olomouc , Czech Republic.
- 700 1_
- $a Malínková, Veronika $u Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Faculty of Science , Palacký University , Šlechtitelů 27 , 783 71 Olomouc , Czech Republic.
- 700 1_
- $a Berka, Karel $u Department of Physical Chemistry, Regional Centre of Advanced Technologies and Materials, Faculty of Science , Palacky University , 17. listopadu 12 , 771 46 Olomouc , Czech Republic.
- 700 1_
- $a Bazgier, Václav, $u Department of Physical Chemistry, Regional Centre of Advanced Technologies and Materials, Faculty of Science , Palacky University , 17. listopadu 12 , 771 46 Olomouc , Czech Republic. $d 1982- $7 ola2015878480
- 700 1_
- $a Ajani, Haresh $u Department of Physical Chemistry, Regional Centre of Advanced Technologies and Materials, Faculty of Science , Palacky University , 17. listopadu 12 , 771 46 Olomouc , Czech Republic. Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences , Flemingovo nám. 2 , 166 10 Prague 6 , Czech Republic.
- 700 1_
- $a Lepšík, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences , Flemingovo nám. 2 , 166 10 Prague 6 , Czech Republic.
- 700 1_
- $a Divoký, Vladimír $u Department of Biology, Faculty of Medicine and Dentistry , Palacký University , Hněvotínská 3 , 775 15 Olomouc , Czech Republic.
- 700 1_
- $a Kryštof, Vladimír $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research , Palacký University and Institute of Experimental Botany AS CR , Šlechtitelů 27 , 783 71 Olomouc , Czech Republic.
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 61, č. 9 (2018), s. 3855-3869
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29672049 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20211207134759 $b ABA008
- 999 __
- $a ok $b bmc $g 1433624 $s 1066935
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 61 $c 9 $d 3855-3869 $e 20180430 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- GRA __
- $a NV15-28951A $p MZ0
- LZP __
- $a Pubmed-20190813